ArticleFrontiers in nutrition2026
Exploring the gut microbiome in type 2 diabetes across different insulin resistance levels: a machine learning approach.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Insulin resistance (IR) is central to type 2 diabetes mellitus (T2DM). Composite indices including the atherogenic index of plasma (AIP), metabolic score for insulin resistance (METS-IR), triglyceride-glucose index (TyG), and TyG-BMI, are widely used to quantify IR severity. The gut microbiome (GM) has been implicated in metabolic dysregulation, but its associations with IR remain incompletely defined. Methods: We collected blood test results and stool samples from participants with T2DM and healthy controls. Stool samples underwent 16S rRNA gene sequencing. We trained XGBoost models to distinguish individuals with higher IR from healthy controls based on GM profiles and performed correlation analyses between GM features, clinical measures, and IR indices. Results: Triglycerides (TG), fasting blood glucose (FBG), and high-density lipoprotein cholesterol (HDL-C) differed significantly between the T2DM and control groups. IR indices (AIP, METS-IR, TyG, and TyG-BMI) were markedly higher in the T2DM group. XGBoost models based on GM profiles showed high discriminatory performance for identifying T2DM individuals with higher IR, with Bacteroides and Faecalibacterium contributing most to model performance. Correlation analyses further indicated that Lachnospiraceae_UCG-010, Bacteroides, Faecalibacterium, Lachnospira, Parasutterella, and Escherichia-Shigella were associated with clinical measures and IR indices. Conclusions: Specific GM features are associated with IR-related clinical measures and composite indices in T2DM, supporting their potential as intervention targets to improve insulin resistance and restore carbohydrate and lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.